{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05683457",
            "orgStudyIdInfo": {
                "id": "mRNA-1647-P205"
            },
            "organization": {
                "fullName": "ModernaTX, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.",
            "officialTitle": "A Phase 2, Observer-Blind, Placebo-Controlled Proof-of-Concept Trial to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation (HCT)",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "a-study-to-evaluate-the-efficacy-safety-and-immunogenicity-of-mrna-cytomegalovirus-cmv-vaccine-in-allogenic-hematopoietic-cell-transplantation-hct-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-08-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-04",
            "studyFirstSubmitQcDate": "2023-01-04",
            "studyFirstPostDateStruct": {
                "date": "2023-01-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ModernaTX, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV prophylactic treatment (for example, letermovir) on Day 100 postHCT through Month 9 postHCT."
        },
        "conditionsModule": {
            "conditions": [
                "Cytomegalovirus Infection"
            ],
            "keywords": [
                "Human cytomegalovirus",
                "Human Herpesvirus",
                "mRNA-1647",
                "Moderna",
                "CMV",
                "Cytomegalovirus Vaccine",
                "Cytomegalovirus Infections",
                "Cytomegalovirus Congenital",
                "Virus Disease",
                "Infection Viral",
                "DNA Virus Infections",
                "Messenger RNA",
                "Hematopoietic cell transplantation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 224,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "mRNA-1647",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive mRNA-1647 vaccine by intramuscular (IM) injection on Day 42, Day 67, and Day 92, and a booster dose on Day 180.",
                    "interventionNames": [
                        "Biological: mRNA-1647"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive mRNA-1647 vaccine matching placebo by IM injection on Day 42, Day 67, and Day 92, and a booster dose on Day 180.",
                    "interventionNames": [
                        "Biological: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "mRNA-1647",
                    "description": "Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).",
                    "armGroupLabels": [
                        "mRNA-1647"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Placebo",
                    "description": "0.9% sodium chloride (normal saline) injection",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Time to the First Occurrence of an CS-CMVi Event as Measured by initiation of anti-CMV Antiviral Therapy",
                    "timeFrame": "Day 100 to Month 9"
                },
                {
                    "measure": "Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)",
                    "timeFrame": "Up to Day 187 (7 days after last study injection)"
                },
                {
                    "measure": "Number of Unsolicited Adverse Events (AEs)",
                    "timeFrame": "Up to Day 205 (25 days after last study injection)"
                },
                {
                    "measure": "Number of Participants with Severe AEs",
                    "timeFrame": "Up to Day 365"
                },
                {
                    "measure": "Number of Participants with Serious Adverse Events (SAEs)",
                    "timeFrame": "Up to Day 365"
                },
                {
                    "measure": "Number of Participants with Grade \u22653 Acute Graft-Versus-Host Disease (GVHD)",
                    "timeFrame": "Up to Day 365"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of Participants with First Occurrence of All CS-CMVi Events as Measured by Initiation of Anti-CMV Antiviral and/or End-Organ Disease",
                    "timeFrame": "Day 100 to Month 9"
                },
                {
                    "measure": "Number of Participants with an Occurrence of CMV Viremia",
                    "description": "CMV Viremia is defined as \u2265300 international units/milliliters (IU/mL).",
                    "timeFrame": "Day 100 to Month 9"
                },
                {
                    "measure": "Number of Participants with CMV End-Organ Disease",
                    "timeFrame": "Day 100 to Month 9"
                },
                {
                    "measure": "Duration of CMV Viremia",
                    "timeFrame": "Day 100 to Month 9"
                },
                {
                    "measure": "Duration of CMV Treatment",
                    "timeFrame": "Day 100 to Month 9"
                },
                {
                    "measure": "Number of Participants with Non-Relapse Mortality at 9 Months PostHCT.",
                    "timeFrame": "Month 9"
                },
                {
                    "measure": "Titer of CMV-Specific Neutralizing Antibody (nAb)",
                    "timeFrame": "Days 42, 67, 92, 117, 180, 205 and 270"
                },
                {
                    "measure": "Geometric Mean Titer (GMT) of Anti-gB-Specific Immunoglobulin G (IgG) and Anti-Pentamer-Specific IgG as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)",
                    "timeFrame": "Days 42, 67, 92, 117, 180, 205 and 270"
                },
                {
                    "measure": "Geometric Mean Concentration (GMC) of Anti-gB-Specific Immunoglobulin G (IgG) and Anti-Pentamer-Specific IgG as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)",
                    "timeFrame": "Days 42, 67, 92, 117, 180, 205 and 270"
                },
                {
                    "measure": "Geometric Mean Fold Rise (GMFR) of Postbaseline/Baseline GMTs or GMCs",
                    "timeFrame": "Days 42, 67, 92, 117, 180, 205 and 270"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Receipt of an allogeneic HCT.\n* CMV-seropositive, defined as a documented positive test for anti-CMV IgG.\n* High-risk for CMV: HCT from related, unrelated, or haploidentical donor with post-transplant cyclophosphamide for graft-versus-host-disease (GVHD) prophylaxis; or HCT from related or unrelated donor with at least one mismatch at any of the following human leukocyte antigen (HLA) gene loci (HLA-A, B, C, and DRB1); or HCT from related or unrelated donor with myeloablative conditioning.\n* Persons of nonchildbearing potential or of childbearing potential with negative urine or serum pregnancy test on the day of first vaccination.\n* Persons of childbearing potential who have practiced adequate contraception or have abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose.\n* Persons of childbearing potential who have agreed to continue adequate contraception or abstain from all activities that could result in pregnancy through 3 months following last vaccination.\n* Persons who are not currently breast/chestfeeding.\n* Willingness to comply with study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* History of a diagnosis or condition that, in the judgment of the Investigator, may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.\n* A documented positive human immunodeficiency virus (HIV) test.\n* Treatment with alemtuzumab (Campath\u00ae), antithymocyte globulin (ATG), or any equivalent in-vivo T cell depleting agent within 12 months.\n* HCT with ex-vivo T cell depletion.\n* Low risk for CMV: HCT from related or unrelated donor with RIC and no other high-risk features.\n* History of prior hematopoietic cell transplantation within 12 months.\n* Receipt of prior investigational CMV vaccines or participation in another CMV therapeutic trial that may interfere with study outcome measures as determined by the Investigator.\n* Suspected or known allergic reaction to any component of any mRNA vaccine or its excipients.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Moderna Clinical Trials Support Center",
                    "role": "CONTACT",
                    "phone": "1-877-777-7187",
                    "email": "clinicaltrials@modernatx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000003586",
                    "term": "Cytomegalovirus Infections"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006566",
                    "term": "Herpesviridae Infections"
                },
                {
                    "id": "D000004266",
                    "term": "DNA Virus Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10283",
                    "name": "Infections",
                    "asFound": "Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6791",
                    "name": "Cytomegalovirus Infections",
                    "asFound": "Cytomegalovirus Infections",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7442",
                    "name": "DNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M9643",
                    "name": "Herpesviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "T1720",
                    "name": "Cytomegalic Inclusion Disease",
                    "asFound": "Cytomegalovirus Infections",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1480",
                    "name": "Congenital Cytomegalovirus",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}